5 Followers HKEX:2196 - Shanghai Fosun Pharmaceutical (Group) Co Ltd

Shanghai Fosun Pharmaceutical
Sector: Health Care, Industry: Pharmaceuticals

Add to Watchlist

•  Default
• New Watchlist

   

Yahoo Finance

• Summary
• Financials
• Dividend
• Prices
• Posts
• User
• Alerts
• Charts

Balance Sheet Cash Flow Income Statement Key Ratios Personalized

Show %	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Graph
Total Assets	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	93.31B 11.5%	107.16B 14.9%	113.47B 5.9%
Current Assets	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	30.44B 21.3%	35.28B 15.9%	33.79B -4.2%
Cash+Equi+Others	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	14.56B 22.0%	17.17B 17.9%	15.58B -9.2%
NonCurrent Assets	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	62.87B 7.3%	71.88B 14.3%	79.68B 10.8%
Total Liabilities	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	44.93B 19.2%	53.05B 18.1%	56.85B 7.2%
Current Liabilities	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	29.32B 17.9%	33.3B 13.6%	33.76B 1.4%
NonCurrent Liabilities	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	15.61B 21.7%	19.76B 26.6%	23.1B 16.9%
Total Equity	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	48.38B 5.2%	54.11B 11.8%	56.62B 4.6%
Stockholders Equity	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	39.2B 5.9%	44.58B 13.7%	45.68B 2.5%
Minority Interest	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	[friend]	9.18B 2.2%	9.53B 3.7%	10.93B 14.7%